TY - JOUR
T1 - State of Transcatheter Aortic Valve Implantation in Spain Versus Europe and Non-European Countries
AU - Biagioni, Corina
AU - Tirado-Conte, Gabriela
AU - Rodés-Cabau, Josep
AU - Ryan, Nicola
AU - Cerrato, Enrico
AU - Nazif, Tamim M
AU - Eltchaninoff, Helene
AU - Sondergaard, Lars
AU - Ribeiro, Henrique B
AU - Barbanti, Marco
AU - Nietlispach, Fabian
AU - De Jaegere, Peter
AU - Agostoni, Pierfrancesco
AU - Trillo, Ramiro
AU - Jiménez-Quevedo, Pilar
AU - D'Ascenzo, Fabrizio
AU - Wendler, Olaf
AU - Maluenda, Gabriel
AU - Chen, Mao
AU - Tamburino, Corrado
AU - Macaya, Carlos
AU - Leon, Martin B
AU - Nombela-Franco, Luis
PY - 2018/8
Y1 - 2018/8
N2 - BACKGROUND: Transcatheter aortic valve implantation (TAVI) is now the standard treatment for severe aortic stenosis in high-risk symptomatic patients, and its indications are expanding to lower-risk patients. OBJECTIVES: The objective of this study was to analyze the state of TAVI in Spain vs other European and non-European countries. METHODS: Using an online questionnaire, we analyzed the routine practice of 250 TAVI centers worldwide. The questionnaire included 59 questions on patient selection, technical aspects of the procedure, and postprocedural management. The centers were divided into Spain (n ≤ 41), rest of Europe (n ≤ 105), and rest of the world (n ≤ 104). RESULTS: The cumulative number of procedures (74; range, 40-122) and those performed in the last year (16.5; range, 15-29.5) in Spain, were significantly lower than the rest of Europe (P<.01) and the rest of the world (P<.01). The patient risk profile was higher, with an under-use of functional tests compared to the rest of the world. While the use of computed tomography to analyze the aortic annulus was lower in Spain (P<.001), general anesthesia and transesophageal echocardiography were more frequently used in Spain than in the rest of Europe (P<.001 for both). Dual-Antiplatelet therapy is the most common post-TAVI antithrombotic therapy in the absence of an indication for anticoagulation, although its duration is longer in Spain (6 months) compared to European centers (3 months). CONCLUSIONS: Routine TAVI practice in Spain differed in some key aspects of preprocedural, intraprocedural, and postprocedural management. Future studies will help to unify strategies and assess their impact on clinical results. TAVI TAVR aortic valve disease transcatheter valve implantation Spain Europe survey.
AB - BACKGROUND: Transcatheter aortic valve implantation (TAVI) is now the standard treatment for severe aortic stenosis in high-risk symptomatic patients, and its indications are expanding to lower-risk patients. OBJECTIVES: The objective of this study was to analyze the state of TAVI in Spain vs other European and non-European countries. METHODS: Using an online questionnaire, we analyzed the routine practice of 250 TAVI centers worldwide. The questionnaire included 59 questions on patient selection, technical aspects of the procedure, and postprocedural management. The centers were divided into Spain (n ≤ 41), rest of Europe (n ≤ 105), and rest of the world (n ≤ 104). RESULTS: The cumulative number of procedures (74; range, 40-122) and those performed in the last year (16.5; range, 15-29.5) in Spain, were significantly lower than the rest of Europe (P<.01) and the rest of the world (P<.01). The patient risk profile was higher, with an under-use of functional tests compared to the rest of the world. While the use of computed tomography to analyze the aortic annulus was lower in Spain (P<.001), general anesthesia and transesophageal echocardiography were more frequently used in Spain than in the rest of Europe (P<.001 for both). Dual-Antiplatelet therapy is the most common post-TAVI antithrombotic therapy in the absence of an indication for anticoagulation, although its duration is longer in Spain (6 months) compared to European centers (3 months). CONCLUSIONS: Routine TAVI practice in Spain differed in some key aspects of preprocedural, intraprocedural, and postprocedural management. Future studies will help to unify strategies and assess their impact on clinical results. TAVI TAVR aortic valve disease transcatheter valve implantation Spain Europe survey.
KW - Aged
KW - Aged, 80 and over
KW - Aortic Valve/surgery
KW - Aortic Valve Stenosis/diagnosis
KW - Echocardiography, Transesophageal
KW - Europe
KW - Female
KW - Humans
KW - Male
KW - Patient Selection
KW - Risk Factors
KW - Spain
KW - Transcatheter Aortic Valve Replacement/statistics & numerical data
KW - United States
M3 - Journal article
C2 - 30068785
SN - 1042-3931
VL - 30
SP - 301
EP - 309
JO - Journal of Invasive Cardiology
JF - Journal of Invasive Cardiology
IS - 8
ER -